SPRINT — Sprint Bioscience AB Cashflow Statement
0.000.00%
Last trade - 00:00- SEK166.71m
- SEK155.77m
- SEK65.64m
Annual cashflow statement for Sprint Bioscience AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -37.8 | -25.6 | -60.7 | -0.845 | -19.7 |
| Depreciation | |||||
| Changes in Working Capital | 4.93 | -15.1 | 1.07 | 23.3 | -4.65 |
| Change in Accounts Receivable | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -32.2 | -40.1 | -59.1 | 22.9 | -23.4 |
| Capital Expenditures | 0 | -2.71 | 0 | -2.45 | -1.3 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0 | — | — | — | — |
| Purchase of Investments | |||||
| Cash from Investing Activities | 0 | -2.71 | 0 | -2.45 | -1.3 |
| Financing Cash Flow Items | -8.02 | -12.4 | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 50.9 | 86.4 | 17.9 | 0.024 | -0.225 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 18.7 | 43.6 | -41.2 | 20.4 | -24.9 |